Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia - Slideshow

Mirum Pharmaceuticals' Phase 3 EXPAND study results for Maralixibat in Cholestatic Pruritus, including Biliary Atresia, were discussed. The company's stock has been volatile in recent months, but some analysts remain bullish on its long-term prospects.

The analyst believes that the company's valuation is reasonable and that the stock is a buy.